Investigating the cardiorespiratory and anti-inflammatory effects of hypoxia-hyperoxia exposure sessions in elderly adults. A randomised controlled trial

Not Applicable

• Conditions: Elderly adults; Cardiovascular - Normal development and function of the cardiovascular system; Inflammatory and Immune System - Normal development and function of the immune system

• Registration Number: ACTRN12624000131550
• Lead Sponsor: niversidad Europea de Madrid

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-02-13
• Last Update Posted: 19 February 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Male
• Target Recruitment: 16

Inclusion Criteria

• Being over 60 years old.
• Having no previous experience in hypoxic training

Exclusion Criteria

• Having any pathology that prevents the performance of physical activity.
• Subjects with impaired cognitive abilities.
• Subjects with pulmonary hypertension, decompensated heart or respiratory failure.
• Subjects who have undergone lower limb surgery within the past 12 months.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood pressure will be assesed using a standard digital sphygmomanometer (Omron HEM-705CP, Omron Healthcare, Inc, Lake Forest, IL)[will be assesed using a standard digital sphygmomanometer (Omron HEM-705CP, Omron Healthcare, Inc, Lake Forest, IL) 24 hours before intervention and 24 hours after intervention];Pulmonary function [will be assessed using the Air Smart Spirometer (Pond Healthcare Innovation, Sweden) 24 hours before intervention and 24 hours after intervention];Heart rate variability and heart rate [will be assessed using a device Polar H10 (Polar Electro Oy, Kempele, Finland). 24 hours before intervention and 24 hours after intervention]

Secondary Outcome Measures

Name	Time	Method
Arterial oxygen saturation [will be assessed using a device Nonin® 3230 (Nonin Medical, Inc. Plymouth, MN, EEUU) 24 hours before intervention and 24 hours after intervention];Maximal inspiratory pressure [will be assessed using the device MicroRPM® (MicroMedical, UK). 24 hours before intervention and 24 hours after intervention];C reactive protein[will be assessed using an ELISA microplate reader (SpectraMax PLUS 384, Molecular Devices, San Jose, CA, USA). 24 hours before intervention and 24 hours after intervention]